Overview
ADIL market data
Price History
ADIL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$11.93 Diluted earnings per share over the trailing twelve months.
- Beta
- -395.14 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.31 – $249.81 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $9.7M · P/B 1.11.
Company News
Adial Pharmaceuticals Says As Of Aug 10, Anticipates Termination Of CEO Cary Claiborne After 2026 Annual Meeting; Anticipates Matthew Davidson To Be Appointed President And CEO; Anticipates Termination Of CFO Vinay Shah After 2026 Annual Meeting; Anticipates Board Changes And Legacy Member ResignationsBenzinga · Aug 13, 2026, 9:30 PM
8-K filing — ADIAL PHARMACEUTICALS, INC. (ADIL)SEC EDGAR · Aug 13, 2026, 9:25 PM
Adial Pharmaceuticals Form 13G Shows Coastlands Capital Partners Discloses 9.98% Passive Stake In Co. As Of June 17Benzinga · Jun 24, 2026, 2:45 PM
LUCID CAPITAL MARKETS Initiates Coverage On Adial Pharmaceuticals with Buy Rating, Announces Price Target of $6Benzinga · Jun 15, 2026, 5:25 PM
Adial Pharmaceuticals shares are trading higher after the company announced it will acquire Azora Therapeutics in an all-stock deal. Also, the company has entered a private placement with potential gross proceeds of up to $64 million.Benzinga · Jun 11, 2026, 4:49 PM
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million FinancingBenzinga · Jun 11, 2026, 4:15 PM
Adial Pharmaceuticals Acquires Azora Therapeutics In All-Stock Transaction, Enters Concurrent Private Placement To Raise Up To $64MBenzinga · Jun 11, 2026, 3:51 PM
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsightGlobenewswire Inc · Jun 8, 2026, 5:15 PM